DexCom (DXCM) Financials

$84.86 -2.12 (-2.44%)

Closing price 04:00 PM Eastern

Extended Trading

$85.67 +0.81 (+0.95%)

As of 07:36 PM Eastern

Annual Income Statements for DexCom

This table shows DexCom's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015
Net Income / (Loss) Attributable to Common Shareholders	576	542	341	217	550	101	-127	-50	-66	-58
Consolidated Net Income / (Loss)	576	542	341	217	550	101	-127	-50	-66	-58
Net Income / (Loss) Continuing Operations	576	542	341	217	550	101	-127	-50	-66	-58
Total Pre-Tax Income	709	710	391	257	298	104	-127	-49	-65	-58
Total Operating Income	600	598	391	266	300	142	-186	-43	-64	-57
Total Gross Profit	2,438	2,289	1,883	1,681	1,280	932	664	492	378	278
Total Revenue	4,033	3,622	2,910	2,449	1,927	1,476	1,032	719	573	402
Operating Revenue	4,033	3,622	2,910	2,449	1,927	1,476	1,032	719	573	402
Total Cost of Revenue	1,595	1,333	1,027	768	647	545	368	226	195	124
Operating Cost of Revenue	1,595	1,333	1,027	768	647	545	368	226	195	124
Total Operating Expenses	1,838	1,691	1,492	1,415	981	789	850	535	442	336
Selling, General & Admin Expense	1,286	1,185	1,008	811	618	516	433	349	286	198
Research & Development Expense	552	506	484	604	360	274	417	185	156	138
Total Other Income / (Expense), net	109	113	-0.40	-9.00	-1.60	-38	60	-6.10	-1.00	-0.40
Other Income / (Expense), net	109	113	-0.40	-9.00	16	26	2.40	6.70	-	-
Income Tax Expense	133	169	50	40	-252	3.10	0.60	1.60	0.70	0.10
Basic Earnings per Share	$1.46	$1.40	$0.88	$0.56	$1.46	$1.11	($1.44)	($0.58)	($0.78)	($0.72)
Weighted Average Basic Shares Outstanding	393.60M	386M	389.40M	386.90M	377.50M	91.10M	88.20M	86.30M	83.60M	79.80M
Diluted Earnings per Share	$1.42	$1.30	$0.82	$0.53	$1.33	$1.10	($1.44)	($0.58)	($0.78)	($0.72)
Weighted Average Diluted Shares Outstanding	412.70M	425.50M	427.50M	428.80M	420.40M	92.30M	88.20M	86.30M	83.60M	79.80M
Weighted Average Basic & Diluted Shares Outstanding	390.77M	385.52M	386.41M	97.07M	96.18M	91.59M	88.20M	86.30M	83.60M	79.80M

This table shows DexCom's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Income / (Loss) Attributable to Common Shareholders	105	152	135	144	146	256	121	116	49	92	101
Consolidated Net Income / (Loss)	105	152	135	144	146	256	121	116	49	92	101
Net Income / (Loss) Continuing Operations	105	152	135	144	146	256	121	116	49	92	101
Total Pre-Tax Income	154	211	177	188	133	246	240	159	65	133	146
Total Operating Income	134	189	152	158	101	217	206	128	47	125	148
Total Gross Profit	589	656	594	627	562	657	623	546	463	541	494
Total Revenue	1,036	1,114	994	1,004	921	1,035	975	871	742	815	770
Operating Revenue	1,036	1,114	994	1,004	921	1,035	975	871	742	815	770
Total Cost of Revenue	447	458	400	378	359	378	352	325	279	274	275
Operating Cost of Revenue	447	458	400	378	359	378	352	325	279	274	275
Total Operating Expenses	455	467	442	469	461	440	418	418	415	416	347
Selling, General & Admin Expense	310	327	306	333	319	304	286	299	296	305	235
Research & Development Expense	145	140	135	136	142	136	131	119	119	116	110
Total Other Income / (Expense), net	21	22	25	30	31	29	35	31	17	7.80	-1.30
Other Income / (Expense), net	21	22	25	30	31	29	35	31	17	-1.30	-1.30
Income Tax Expense	49	60	43	44	-14	-10	120	43	16	41	45
Basic Earnings per Share	$0.27	$0.38	$0.34	$0.36	$0.38	$0.66	$0.31	$0.30	$0.13	$0.24	$0.26
Weighted Average Basic Shares Outstanding	391.10M	393.60M	394.20M	399.20M	390.20M	386M	386.60M	386.70M	386.70M	389.40M	389.80M
Diluted Earnings per Share	$0.27	$0.37	$0.34	$0.35	$0.36	$0.66	$0.29	$0.28	$0.12	$0.24	$0.24
Weighted Average Diluted Shares Outstanding	407.50M	412.70M	410.20M	416.80M	416.70M	425.50M	426.80M	431.50M	418.50M	427.50M	425.80M
Weighted Average Basic & Diluted Shares Outstanding	392.11M	390.77M	390.60M	400.73M	397.68M	385.52M	386.37M	387.87M	387.64M	386.41M	386.26M

This table details how cash moves in and out of DexCom's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015
Net Change in Cash & Equivalents	40	-76	-410	235	372	-691	694	347	8.40	14
Net Cash From Operating Activities	990	749	670	443	476	315	123	92	56	49
Net Cash From Continuing Operating Activities	990	749	670	443	476	310	123	92	56	49
Net Income / (Loss) Continuing Operations	576	542	341	217	550	101	-127	-50	-66	-58
Consolidated Net Income / (Loss)	576	542	341	217	550	101	-127	-50	-66	-58
Depreciation Expense	218	186	156	102	67	49	29	16	15	11
Non-Cash Adjustments To Reconcile Net Income	131	73	167	240	140	154	264	114	113	121
Changes in Operating Assets and Liabilities, net	65	-52	5.10	-116	-281	6.30	-43	2.60	-6.30	-25
Net Cash From Investing Activities	-208	-507	-522	-216	-1,018	-1,015	-140	-144	-56	-52
Net Cash From Continuing Investing Activities	-208	-507	-522	-216	-1,018	-1,015	-140	-144	-56	-52
Purchase of Property, Plant & Equipment	-359	-237	-365	-389	-199	-180	-67	-66	-56	-33
Acquisitions	0.00	0.00	-3.90	-30	0.00	0.00	-11	0.00	0.30	-0.50
Purchase of Investments	-2,658	-3,220	-2,281	-2,473	-3,058	-2,030	-453	-172	-39	-45
Sale and/or Maturity of Investments	2,824	2,947	2,128	2,666	2,251	1,196	392	93	39	28
Other Investing Activities, net	-16	1.90	0.20	10	-11	-1.20	-1.00	-	-	-
Net Cash From Financing Activities	-735	-319	-553	10	912	11	710	399	8.10	17
Net Cash From Continuing Financing Activities	-735	-319	-553	10	912	11	710	399	8.10	17
Repayment of Debt	-13	-786	-17	-9.90	-9.40	-1.20	-1.90	-75	-2.30	-2.30
Repurchase of Common Equity	-750	-689	-558	0.00	0.00	-	-100	0.00	0.00	-
Issuance of Debt	0.00	1,231	0.00	0.00	1,189	0.00	837	464	0.00	0.00
Issuance of Common Equity	28	27	23	20	15	12	195	10	10	19
Other Financing Activities, net	0.00	-101	0.00	0.00	-	-	-219	0.00	0.00	-
Effect of Exchange Rate Changes	-7.40	1.50	-5.80	-1.40	2.10	-0.70	-	-	0.00	0.00
Cash Interest Paid	11	12	12	12	11	10	3.60	2.40	0.10	0.30
Cash Income Taxes Paid	198	212	114	17	3.60	4.80	2.30	1.40	0.10	0.10

This table details how cash moves in and out of DexCom's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Change in Cash & Equivalents	299	-15	-318	88	285	-77	-551	572	-19	-56	-37
Net Cash From Operating Activities	184	301	200	279	209	134	269	190	155	133	293
Net Cash From Continuing Operating Activities	184	301	200	279	209	134	269	190	155	132	293
Net Income / (Loss) Continuing Operations	105	152	135	144	146	256	121	116	49	92	101
Consolidated Net Income / (Loss)	105	152	135	144	146	256	121	116	49	92	101
Depreciation Expense	60	58	55	52	53	53	48	44	42	36	39
Non-Cash Adjustments To Reconcile Net Income	24	61	5.40	31	33	1.40	22	35	14	38	48
Changes in Operating Assets and Liabilities, net	-5.40	31	4.20	53	-23	-177	78	-4.70	52	-34	105
Net Cash From Investing Activities	100	-304	210	-189	75	415	-180	-556	-187	-194	229
Net Cash From Continuing Investing Activities	100	-304	210	-189	75	415	-180	-556	-187	-194	229
Purchase of Property, Plant & Equipment	-87	-125	-111	-66	-57	-53	-50	-59	-75	-64	-108
Purchase of Investments	-463	-574	-307	-784	-992	-272	-798	-1,340	-810	-883	-254
Sale and/or Maturity of Investments	650	405	631	667	1,122	719	671	859	698	740	602
Other Investing Activities, net	-0.50	-10	-2.20	-5.40	2.30	20	-2.50	-16	0.00	13	-10
Net Cash From Financing Activities	13	-1.60	-737	-1.40	4.70	-632	-637	940	11	-1.00	-553
Net Cash From Continuing Financing Activities	13	-1.60	-737	-1.40	4.70	-632	-637	940	11	-1.00	-553
Repayment of Debt	-1.70	-1.60	-1.30	-1.40	-8.70	-132	-652	-1.10	-1.10	-1.00	-7.20
Issuance of Common Equity	14	-	15	-	13	-	14	-	12	-	12
Effect of Exchange Rate Changes	2.30	-11	8.60	-1.00	-3.80	6.10	-3.50	-2.20	1.10	6.80	-7.30

This table presents DexCom's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015
Total Assets	6,485	6,265	5,392	4,933	4,291	2,395	1,916	904	403	292
Total Current Assets	4,301	4,426	3,669	3,684	3,425	1,969	1,700	745	280	231
Cash & Equivalents	606	566	642	1,053	818	446	1,137	442	95	86
Short-Term Investments	1,973	2,158	1,814	1,679	1,890	1,087	249	107	29	29
Accounts Receivable	1,006	974	713	514	429	286	227	134	102	74
Inventories, net	543	560	307	357	235	120	71	45	45	35
Prepaid Expenses	174	168	193	82	54	30	17	17	9.20	6.80
Plant, Property, & Equipment, net	1,340	1,113	1,056	802	515	321	183	146	109	55
Total Noncurrent Assets	843	726	667	447	350	104	33	14	13	6.00
Goodwill	23	25	26	27	19	19	19	12	11	3.70
Intangible Assets	103	135	173	32	-	-	-	-	-	2.20
Noncurrent Deferred & Refundable Income Taxes	481	419	341	291	216	0.00	-	-	-	-
Other Noncurrent Operating Assets	236	146	127	99	115	86	15	1.70	2.10	0.10
Total Liabilities & Shareholders' Equity	6,485	6,265	5,392	4,933	4,291	2,395	1,916	904	403	292
Total Liabilities	4,382	4,196	3,260	2,891	2,464	1,512	1,253	485	119	71
Total Current Liabilities	2,932	1,556	1,839	721	614	360	222	139	102	67
Short-Term Debt	1,204	0.00	773	0.00	-	-	-	-	-	2.30
Accounts Payable	1,585	1,346	902	573	481	256	147	87	68	39
Current Deferred Revenue	8.00	18	10	2.10	2.20	1.70	2.90	3.20	0.90	0.80
Current Employee Benefit Liabilities	112	171	134	125	114	89	72	49	33	25
Other Current Liabilities	23	21	21	21	17	14	0.00	-	-	-
Total Noncurrent Liabilities	1,450	2,640	1,421	2,170	1,850	1,152	1,030	346	17	3.90
Long-Term Debt	1,237	2,434	1,198	1,982	1,667	1,060	1,010	328	0.00	-
Other Noncurrent Operating Liabilities	213	206	223	189	183	93	20	18	17	3.90
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	2,103	2,069	2,132	2,042	1,827	883	663	419	284	221
Total Preferred & Common Equity	2,103	2,069	2,132	2,042	1,827	883	663	419	284	221
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	2,103	2,069	2,132	2,042	1,827	883	663	419	284	221
Common Stock	2,094	3,515	2,259	2,109	2,125	1,676	1,561	1,094	906	777
Retained Earnings	1,598	1,021	480	139	-202	-696	-799	-672	-621	-555
Treasury Stock	-1,581	-2,451	-595	-206	-100	-100	-100	0.00	-	-
Accumulated Other Comprehensive Income / (Loss)	-8.00	-17	-12	0.50	3.20	2.30	1.50	-2.60	-1.00	-0.30

This table presents DexCom's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Total Assets	6,752	6,485	6,354	6,799	6,482	6,265	6,596	6,821	5,516	5,392	4,899
Total Current Assets	4,554	4,301	4,263	4,848	4,621	4,426	4,698	5,003	3,767	3,669	3,399
Cash & Equivalents	905	606	621	939	851	566	644	1,195	623	642	698
Short-Term Investments	1,797	1,973	1,871	2,182	2,046	2,158	2,597	2,441	1,944	1,814	1,674
Accounts Receivable	1,155	1,006	1,002	945	979	974	786	751	637	713	564
Inventories, net	538	543	586	570	589	560	499	421	366	307	311
Prepaid Expenses	159	174	182	212	156	168	174	195	198	193	152
Plant, Property, & Equipment, net	1,365	1,340	1,319	1,183	1,109	1,113	1,079	1,078	1,076	1,056	1,003
Total Noncurrent Assets	833	843	772	768	753	726	819	740	673	667	498
Goodwill	23	23	24	23	23	25	25	26	26	26	25
Intangible Assets	95	103	106	115	123	135	145	154	164	173	24
Noncurrent Deferred & Refundable Income Taxes	487	481	487	476	461	419	501	417	349	341	342
Other Noncurrent Operating Assets	228	236	156	154	146	146	148	143	135	127	107
Total Liabilities & Shareholders' Equity	6,752	6,485	6,354	6,799	6,482	6,265	6,596	6,821	5,516	5,392	4,899
Total Liabilities	4,485	4,382	4,375	4,365	4,235	4,196	4,328	4,720	3,283	3,260	3,075
Total Current Liabilities	3,037	2,932	1,735	1,722	1,594	1,556	1,679	2,070	1,865	1,839	901
Short-Term Debt	1,205	1,204	-	-	-	0.00	124	774	773	773	-
Accounts Payable	1,691	1,585	1,593	1,570	1,447	1,346	1,373	1,157	965	902	764
Current Deferred Revenue	7.80	8.00	14	15	16	18	9.00	9.00	9.60	10	2.70
Current Employee Benefit Liabilities	111	112	106	116	111	171	151	109	95	134	113
Other Current Liabilities	23	23	22	22	21	21	21	22	22	21	21
Total Noncurrent Liabilities	1,448	1,450	2,640	2,643	2,641	2,640	2,650	2,651	1,418	1,421	2,174
Long-Term Debt	1,238	1,237	2,440	2,438	2,436	2,434	2,432	2,431	1,199	1,198	1,969
Other Noncurrent Operating Liabilities	210	213	201	205	205	206	217	220	219	223	205
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	2,267	2,103	1,979	2,434	2,247	2,069	2,268	2,100	2,233	2,132	1,825
Total Preferred & Common Equity	2,267	2,103	1,979	2,434	2,247	2,069	2,268	2,100	2,233	2,132	1,825
Preferred Stock	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Common Equity	2,267	2,103	1,979	2,434	2,247	2,069	2,268	2,100	2,233	2,132	1,825
Common Stock	2,143	2,094	2,051	1,993	2,511	3,515	3,618	2,269	2,306	2,259	2,073
Retained Earnings	1,703	1,598	1,446	1,311	1,168	1,021	765	644	529	480	388
Treasury Stock	-1,581	-1,581	-1,581	-832	-	-2,451	-2,080	-784	-595	-595	-595
Accumulated Other Comprehensive Income / (Loss)	2.20	-8.00	63	-38	-37	-17	-36	-29	-6.50	-12	-41

This table displays calculated financial ratios and metrics derived from DexCom's official financial filings.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	11.34%	24.49%	18.84%	27.08%	30.54%	43.08%	43.58%	25.33%	42.61%	55.09%
EBITDA Growth	3.38%	63.97%	52.37%	-6.25%	76.04%	240.44%	-1,402.91%	78.89%	-5.86%	-251.91%
EBIT Growth	-0.20%	81.78%	52.18%	-18.63%	87.08%	191.73%	-413.69%	43.98%	-11.91%	-165.58%
NOPAT Growth	7.03%	33.39%	52.14%	-59.38%	300.28%	205.87%	-338.35%	33.49%	-11.91%	-165.58%
Net Income Growth	6.41%	58.70%	57.31%	-60.54%	443.72%	179.54%	-153.19%	23.48%	-13.89%	-157.14%
EPS Growth	9.23%	58.54%	54.72%	-60.54%	443.72%	176.39%	-148.28%	25.64%	-8.33%	-140.00%
Operating Cash Flow Growth	32.20%	11.80%	51.30%	-6.96%	51.22%	155.28%	33.91%	63.70%	14.69%	107.63%
Free Cash Flow Firm Growth	-6.53%	2,870.59%	95.87%	-260.66%	929.22%	107.76%	-223.31%	29.50%	-9.61%	-120.45%
Invested Capital Growth	10.45%	8.07%	27.32%	64.47%	92.18%	42.01%	45.16%	23.92%	47.83%	79.90%
Revenue Q/Q Growth	2.00%	6.44%	4.19%	5.58%	5.83%	9.24%	12.79%	7.45%	7.58%	13.08%
EBITDA Q/Q Growth	-3.10%	18.24%	33.11%	-22.12%	0.63%	369.06%	-616.00%	73.86%	-16.47%	1.91%
EBIT Q/Q Growth	-4.69%	20.75%	50.89%	-30.67%	-1.16%	236.27%	-1,795.88%	40.92%	-13.70%	0.00%
NOPAT Q/Q Growth	-15.16%	42.62%	38.66%	-61.16%	91.63%	259.32%	-1,736.15%	29.87%	-13.70%	0.00%
Net Income Q/Q Growth	-15.36%	43.63%	39.78%	-65.76%	137.86%	159.02%	-394.21%	-4.15%	-15.70%	0.35%
EPS Q/Q Growth	-17.92%	32.65%	30.16%	-65.76%	137.86%	158.51%	-400.00%	-1.75%	-18.18%	0.00%
Operating Cash Flow Q/Q Growth	20.42%	0.15%	4.15%	-13.01%	6.33%	53.79%	-5.74%	43.53%	3.69%	6.29%
Free Cash Flow Firm Q/Q Growth	29.70%	106.07%	65.10%	-1,163.91%	36.60%	107.24%	-284.62%	24.49%	-6.15%	-12.09%
Invested Capital Q/Q Growth	1.99%	12.28%	15.79%	13.23%	45.21%	7.21%	23.98%	8.89%	19.03%	30.64%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	60.46%	63.19%	64.72%	68.63%	66.44%	63.11%	64.36%	68.49%	66.00%	69.25%
EBITDA Margin	22.98%	24.75%	18.79%	14.65%	19.86%	14.73%	-15.01%	-1.43%	-8.51%	-11.47%
Operating Margin	14.88%	16.50%	13.44%	10.86%	15.54%	9.64%	-18.06%	-5.92%	-11.15%	-14.20%
EBIT Margin	17.58%	19.61%	13.43%	10.49%	16.38%	11.43%	-17.83%	-4.98%	-11.15%	-14.20%
Profit (Net Income) Margin	14.29%	14.95%	11.73%	8.86%	28.53%	6.85%	-12.32%	-6.99%	-11.44%	-14.33%
Tax Burden Percent	81.27%	76.22%	87.31%	84.46%	184.53%	97.03%	100.47%	103.29%	101.08%	100.17%
Interest Burden Percent	100.00%	100.00%	100.00%	100.00%	94.39%	61.77%	68.79%	135.75%	101.56%	100.70%
Effective Tax Rate	18.73%	23.78%	12.69%	15.54%	-84.53%	2.98%	0.00%	0.00%	0.00%	0.00%
Return on Invested Capital (ROIC)	26.05%	26.61%	23.25%	21.60%	92.49%	39.62%	-53.62%	-16.60%	-33.33%	-47.44%
ROIC Less NNEP Spread (ROIC-NNEP)	-15.35%	4.46%	23.30%	22.45%	92.88%	48.33%	-54.73%	-4.73%	-15.69%	-29.16%
Return on Net Nonoperating Assets (RNNOA)	1.57%	-0.82%	-6.90%	-10.39%	-51.91%	-26.54%	30.14%	2.32%	7.35%	15.57%
Return on Equity (ROE)	27.63%	25.78%	16.35%	11.21%	40.58%	13.08%	-23.48%	-14.28%	-25.98%	-31.88%
Cash Return on Invested Capital (CROIC)	16.12%	18.85%	-0.79%	-27.15%	29.40%	4.90%	-90.46%	-37.96%	-71.93%	-104.53%
Operating Return on Assets (OROA)	11.12%	12.19%	7.57%	5.57%	9.44%	7.83%	-13.04%	-5.48%	-18.39%	-23.96%
Return on Assets (ROA)	9.04%	9.29%	6.61%	4.70%	16.44%	4.69%	-9.01%	-7.68%	-18.88%	-24.17%
Return on Common Equity (ROCE)	27.63%	25.78%	16.35%	11.21%	40.58%	13.08%	-23.48%	-14.28%	-25.98%	-31.88%
Return on Equity Simple (ROE_SIMPLE)	27.40%	26.18%	16.01%	10.62%	30.10%	11.45%	-19.16%	-11.97%	-23.11%	-26.04%
Net Operating Profit after Tax (NOPAT)	488	456	342	225	553	138	-130	-30	-45	-40
NOPAT Margin	12.09%	12.58%	11.74%	9.17%	28.68%	9.35%	-12.64%	-4.14%	-7.80%	-9.94%
Net Nonoperating Expense Percent (NNEP)	41.40%	22.15%	-0.06%	-0.85%	-0.39%	-8.71%	1.11%	-11.87%	-17.64%	-18.28%
Return On Investment Capital (ROIC_SIMPLE)	10.73%	10.12%	8.33%	-	-	-	-	-	-	-
Cost of Revenue to Revenue	39.54%	36.81%	35.28%	31.37%	33.56%	36.89%	35.64%	31.51%	34.00%	30.75%
SG&A Expenses to Revenue	31.88%	32.73%	34.63%	33.10%	32.09%	34.94%	41.95%	48.60%	49.92%	49.25%
R&D to Revenue	13.70%	13.96%	16.64%	24.68%	18.68%	18.53%	40.46%	25.80%	27.23%	34.20%
Operating Expenses to Revenue	45.58%	46.69%	51.27%	57.78%	50.90%	53.47%	82.42%	74.41%	77.15%	83.46%
Earnings before Interest and Taxes (EBIT)	709	710	391	257	316	169	-184	-36	-64	-57
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	927	896	547	359	383	217	-155	-10	-49	-46
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	14.45	23.18	20.52	6.37	4.86	5.67	4.01	2.97	4.45	7.52
Price to Tangible Book Value (P/TBV)	15.37	25.12	22.63	6.56	4.91	5.79	4.13	3.06	4.63	7.73
Price to Revenue (P/Rev)	7.53	13.24	15.03	5.31	4.61	3.39	2.58	1.74	2.20	4.14
Price to Earnings (P/E)	52.72	88.54	128.19	59.98	16.15	49.51	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	1.90%	1.13%	0.78%	1.67%	6.19%	2.02%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	15.39	26.79	26.28	9.48	9.97	11.08	7.94	5.17	7.11	14.33
Enterprise Value to Revenue (EV/Rev)	7.50	13.16	14.86	5.01	4.07	3.07	2.22	1.43	1.98	3.86
Enterprise Value to EBITDA (EV/EBITDA)	32.63	53.16	79.12	34.17	20.47	20.84	0.00	0.00	0.00	0.00
Enterprise Value to EBIT (EV/EBIT)	42.65	67.08	110.68	47.75	24.83	26.86	0.00	0.00	0.00	0.00
Enterprise Value to NOPAT (EV/NOPAT)	62.01	104.60	126.64	54.62	14.18	32.82	0.00	0.00	0.00	0.00
Enterprise Value to Operating Cash Flow (EV/OCF)	30.56	63.67	64.61	27.71	16.47	14.41	18.55	11.15	20.25	31.67
Enterprise Value to Free Cash Flow (EV/FCFF)	100.22	147.63	0.00	0.00	44.61	265.53	0.00	0.00	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	1.16	1.18	0.92	0.97	0.91	1.20	1.52	0.78	0.00	0.01
Long-Term Debt to Equity	0.59	1.18	0.56	0.97	0.91	1.20	1.52	0.78	0.00	0.00
Financial Leverage	-0.10	-0.18	-0.30	-0.46	-0.56	-0.55	-0.55	-0.49	-0.47	-0.53
Leverage Ratio	3.06	2.78	2.47	2.38	2.47	2.79	2.60	1.86	1.38	1.32
Compound Leverage Factor	3.06	2.78	2.47	2.38	2.33	1.72	1.79	2.52	1.40	1.33
Debt to Total Capital	53.73%	54.06%	48.03%	49.25%	47.72%	54.56%	60.37%	43.86%	0.00%	1.03%
Short-Term Debt to Total Capital	26.51%	0.00%	18.83%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	1.03%
Long-Term Debt to Total Capital	27.22%	54.06%	29.20%	49.25%	47.72%	54.56%	60.37%	43.86%	0.00%	0.00%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	46.27%	45.94%	51.97%	50.75%	52.28%	45.44%	39.63%	56.14%	100.00%	98.97%
Debt to EBITDA	2.63	2.72	3.60	5.52	4.36	4.87	-6.53	-31.81	0.00	-0.05
Net Debt to EBITDA	-0.15	-0.32	-0.89	-2.09	-2.72	-2.18	2.42	21.46	0.00	2.45
Long-Term Debt to EBITDA	1.33	2.72	2.19	5.52	4.36	4.87	-6.53	-31.81	0.00	0.00
Debt to NOPAT	5.01	5.34	5.77	8.83	3.02	7.68	-7.75	-11.01	0.00	-0.06
Net Debt to NOPAT	-0.28	-0.64	-1.42	-3.34	-1.88	-3.43	2.88	7.43	0.00	2.82
Long-Term Debt to NOPAT	2.54	5.34	3.51	8.83	3.02	7.68	-7.75	-11.01	0.00	0.00
Altman Z-Score	5.74	8.59	9.36	4.13	3.57	3.23	1.84	1.97	5.63	12.85
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	1.47	2.84	1.99	5.11	5.58	5.47	7.64	5.36	2.73	3.46
Quick Ratio	1.22	2.38	1.72	4.50	5.11	5.05	7.25	4.92	2.20	2.83
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	302	323	-12	-282	176	17	-220	-68	-97	-88
Operating Cash Flow to CapEx	275.78%	316.36%	183.53%	113.69%	239.00%	174.72%	183.61%	139.39%	100.90%	147.15%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	9.92	0.28	-9.69	-5.32	-96.53	-220.18
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	26.87	5.22	5.43	7.19	56.20	122.50
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	15.63	2.23	2.47	2.03	0.50	39.25
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.63	0.62	0.56	0.53	0.58	0.68	0.73	1.10	1.65	1.69
Accounts Receivable Turnover	4.07	4.29	4.74	5.19	5.39	5.75	5.72	6.09	6.52	6.90
Inventory Turnover	2.89	3.08	3.09	2.59	3.65	5.72	6.35	5.00	4.84	4.83
Fixed Asset Turnover	3.29	3.34	3.13	3.72	4.61	5.85	6.28	5.64	6.99	9.36
Accounts Payable Turnover	1.09	1.19	1.39	1.46	1.75	2.70	3.14	2.92	3.64	4.17
Days Sales Outstanding (DSO)	89.58	85.01	76.99	70.27	67.71	63.43	63.86	59.94	55.96	52.89
Days Inventory Outstanding (DIO)	126.13	118.57	118.03	140.68	100.06	63.85	57.52	73.03	75.47	75.60
Days Payable Outstanding (DPO)	335.36	307.58	262.15	250.49	208.16	135.24	116.29	125.19	100.19	87.56
Cash Conversion Cycle (CCC)	-119.65	-104.01	-67.13	-39.54	-40.39	-7.96	5.10	7.79	31.24	40.93
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	1,965	1,779	1,646	1,293	786	409	288	198	160	108
Invested Capital Turnover	2.15	2.12	1.98	2.36	3.22	4.24	4.24	4.01	4.27	4.77
Increase / (Decrease) in Invested Capital	186	133	353	507	377	121	90	38	52	48
Enterprise Value (EV)	30,239	47,655	43,254	12,261	7,835	4,532	2,286	1,026	1,138	1,552
Market Capitalization	30,377	47,945	43,740	13,011	8,876	5,005	2,661	1,247	1,262	1,665
Book Value per Share	$5.38	$5.35	$5.52	$21.07	$19.02	$9.64	$7.47	$4.83	$3.36	$2.72
Tangible Book Value per Share	$5.06	$4.94	$5.00	$20.47	$18.82	$9.44	$7.26	$4.69	$3.22	$2.65
Total Capital	4,544	4,503	4,102	4,024	3,494	1,942	1,674	747	284	224
Total Debt	2,441	2,434	1,970	1,982	1,667	1,060	1,010	328	0.00	2.30
Total Long-Term Debt	1,237	2,434	1,198	1,982	1,667	1,060	1,010	328	0.00	0.00
Net Debt	-138	-290	-486	-749	-1,041	-474	-375	-221	-124	-113
Capital Expenditures (CapEx)	359	237	365	389	199	180	67	66	56	33
Debt-free, Cash-free Net Working Capital (DFCFNWC)	-5.60	146	146	232	103	76	92	57	54	52
Debt-free Net Working Capital (DFNWC)	2,574	2,870	2,602	2,964	2,811	1,609	1,477	606	178	167
Net Working Capital (NWC)	1,369	2,870	1,830	2,964	2,811	1,609	1,477	606	178	164
Net Nonoperating Expense (NNE)	-89	-86	0.35	7.60	2.95	37	-3.31	20	21	18
Net Nonoperating Obligations (NNO)	-138	-290	-486	-749	-1,041	-474	-375	-221	-124	-113
Total Depreciation and Amortization (D&A)	218	186	156	102	67	49	29	26	15	11
Debt-free, Cash-free Net Working Capital to Revenue	-0.14%	4.03%	5.01%	9.49%	5.35%	5.14%	8.87%	7.96%	9.40%	12.81%
Debt-free Net Working Capital to Revenue	63.82%	79.23%	89.43%	121.04%	145.88%	109.02%	143.19%	84.31%	30.98%	41.47%
Net Working Capital to Revenue	33.95%	79.23%	62.87%	121.04%	145.88%	109.02%	143.19%	84.31%	30.98%	40.90%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$1.46	$1.40	$0.88	$1.60	$5.23	$1.11	($1.44)	($0.58)	($0.78)	($0.72)
Adjusted Weighted Average Basic Shares Outstanding	393.60M	386M	389.40M	96.70M	94.40M	91.10M	90.00M	87.00M	84.82M	81.74M
Adjusted Diluted Earnings per Share	$1.42	$1.30	$0.82	$1.55	$5.06	$1.10	($1.44)	($0.58)	($0.78)	($0.72)
Adjusted Weighted Average Diluted Shares Outstanding	412.70M	425.50M	427.50M	100.10M	97.50M	92.30M	90.00M	87.00M	84.82M	81.74M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	($1.44)	($0.58)	($0.78)	($0.72)
Adjusted Weighted Average Basic & Diluted Shares Outstanding	390.77M	385.52M	386.41M	97.07M	96.18M	91.59M	88.20M	86.30M	83.60M	79.80M
Normalized Net Operating Profit after Tax (NOPAT)	488	456	342	225	210	138	-130	-30	-45	-40
Normalized NOPAT Margin	12.09%	12.58%	11.74%	9.17%	10.88%	9.35%	-12.64%	-4.14%	-7.80%	-9.94%
Pre Tax Income Margin	17.58%	19.61%	13.43%	10.49%	15.46%	7.06%	-12.26%	-6.76%	-11.32%	-14.30%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	17.83	2.80	-8.10	-2.80	-63.90	-142.75
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	31.22	2.29	-5.74	-2.32	-44.73	-99.93
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	6.59	-0.19	-11.06	-7.95	-119.60	-226.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	19.98	-0.70	-8.70	-7.48	-100.43	-183.18
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	130.16%	127.18%	163.45%	0.00%	0.00%	0.00%	-78.68%	0.00%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from DexCom's official financial filings.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	12.49%	7.64%	1.97%	15.26%	24.21%	26.90%	26.69%	25.15%	17.92%	16.76%	18.36%
EBITDA Growth	15.84%	-9.91%	-19.37%	18.18%	74.36%	86.22%	55.66%	64.24%	37.26%	557.38%	30.47%
EBIT Growth	16.45%	-14.18%	-26.21%	17.89%	105.43%	98.39%	64.43%	99.13%	59.26%	1,711.69%	25.39%
NOPAT Growth	-18.24%	-39.94%	11.78%	29.54%	214.09%	161.27%	1.06%	79.06%	-68.05%	17,493.57%	10.72%
Net Income Growth	-28.01%	-40.81%	11.52%	23.81%	201.23%	179.19%	19.27%	127.70%	-50.05%	1,832.08%	15.92%
EPS Growth	-25.00%	-43.94%	17.24%	25.00%	200.00%	175.00%	20.83%	133.33%	-47.83%	2,500.00%	14.29%
Operating Cash Flow Growth	-12.14%	125.60%	-25.89%	46.82%	34.62%	0.83%	-8.19%	10.13%	118.87%	25.24%	18.56%
Free Cash Flow Firm Growth	-260.97%	-154.07%	-280.35%	135.45%	73.07%	134.86%	66.43%	63.48%	65.90%	47.40%	65.05%
Invested Capital Growth	12.47%	10.45%	21.59%	4.96%	9.04%	8.07%	11.45%	13.63%	11.64%	27.32%	24.50%
Revenue Q/Q Growth	-6.96%	12.00%	-1.01%	9.04%	-10.97%	6.10%	11.90%	17.51%	-9.04%	5.93%	10.54%
EBITDA Q/Q Growth	-20.36%	15.64%	-3.00%	29.68%	-38.27%	3.50%	42.17%	91.33%	-33.85%	-13.48%	50.00%
EBIT Q/Q Growth	-26.98%	19.11%	-5.54%	41.74%	-46.40%	2.41%	50.91%	146.98%	-48.03%	-15.12%	82.75%
NOPAT Q/Q Growth	-32.66%	17.59%	-4.47%	8.08%	-50.53%	118.84%	10.71%	162.06%	-58.85%	-15.35%	96.16%
Net Income Q/Q Growth	-30.52%	12.70%	-6.20%	-1.98%	-42.88%	112.34%	4.14%	138.48%	-47.06%	-9.29%	98.82%
EPS Q/Q Growth	-27.03%	8.82%	-2.86%	-2.78%	-45.45%	127.59%	3.57%	133.33%	-50.00%	0.00%	100.00%
Operating Cash Flow Q/Q Growth	-39.02%	51.08%	-28.60%	33.56%	56.59%	-50.37%	41.46%	22.46%	17.28%	-54.81%	69.68%
Free Cash Flow Firm Q/Q Growth	-161.27%	77.83%	-697.88%	204.22%	-139.13%	255.98%	44.28%	20.82%	49.35%	-50.21%	39.38%
Invested Capital Q/Q Growth	2.23%	1.99%	9.99%	-1.93%	0.40%	12.28%	-5.06%	1.89%	-0.50%	15.79%	-3.20%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	56.85%	58.90%	59.73%	62.40%	61.01%	63.47%	63.93%	62.71%	62.39%	66.40%	64.22%
EBITDA Margin	20.69%	24.17%	23.41%	23.89%	20.09%	28.87%	29.60%	23.30%	14.31%	19.68%	24.09%
Operating Margin	12.91%	16.96%	15.29%	15.73%	10.98%	20.97%	21.08%	14.70%	6.37%	15.38%	19.17%
EBIT Margin	14.89%	18.98%	17.84%	18.70%	14.39%	23.80%	24.66%	18.28%	8.70%	15.22%	19.00%
Profit (Net Income) Margin	10.17%	13.62%	13.54%	14.29%	15.90%	24.78%	12.38%	13.30%	6.55%	11.26%	13.15%
Tax Burden Percent	68.31%	71.79%	75.87%	76.41%	110.49%	104.10%	50.21%	72.76%	75.35%	68.92%	69.22%
Interest Burden Percent	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	100.00%	107.33%	100.00%
Effective Tax Rate	31.69%	28.21%	24.13%	23.59%	-10.49%	-4.10%	49.79%	27.24%	24.65%	31.08%	30.78%
Return on Invested Capital (ROIC)	19.27%	26.24%	26.13%	27.66%	26.94%	46.17%	23.96%	21.81%	9.34%	21.00%	28.91%
ROIC Less NNEP Spread (ROIC-NNEP)	15.36%	18.73%	20.90%	23.58%	20.37%	38.31%	20.74%	18.08%	7.36%	20.13%	29.04%
Return on Net Nonoperating Assets (RNNOA)	-2.45%	-1.92%	-3.62%	-5.80%	-4.80%	-7.08%	-5.51%	-5.06%	-2.19%	-5.96%	-10.25%
Return on Equity (ROE)	16.83%	24.32%	22.51%	21.87%	22.14%	39.10%	18.46%	16.75%	7.15%	15.04%	18.66%
Cash Return on Invested Capital (CROIC)	12.68%	16.12%	13.25%	28.10%	22.61%	18.85%	10.42%	7.54%	6.85%	-0.79%	-2.60%
Operating Return on Assets (OROA)	9.34%	12.01%	10.90%	10.80%	9.12%	14.79%	14.60%	9.71%	4.97%	8.58%	10.97%
Return on Assets (ROA)	6.38%	8.62%	8.27%	8.26%	10.07%	15.40%	7.33%	7.07%	3.75%	6.35%	7.59%
Return on Common Equity (ROCE)	16.83%	24.32%	22.51%	21.87%	22.14%	39.10%	18.46%	16.75%	7.15%	15.04%	18.66%
Return on Equity Simple (ROE_SIMPLE)	23.61%	0.00%	34.40%	27.40%	28.45%	0.00%	16.62%	17.02%	13.10%	0.00%	13.38%
Net Operating Profit after Tax (NOPAT)	91	136	115	121	112	226	103	93	36	86	102
NOPAT Margin	8.82%	12.18%	11.60%	12.02%	12.13%	21.83%	10.58%	10.70%	4.80%	10.60%	13.27%
Net Nonoperating Expense Percent (NNEP)	3.91%	7.52%	5.23%	4.09%	6.57%	7.86%	3.22%	3.72%	1.98%	0.87%	-0.13%
Return On Investment Capital (ROIC_SIMPLE)	1.94%	2.98%	-	-	-	5.01%	-	-	-	2.11%	-
Cost of Revenue to Revenue	43.15%	41.10%	40.27%	37.60%	38.99%	36.53%	36.07%	37.29%	37.61%	33.60%	35.78%
SG&A Expenses to Revenue	29.93%	29.40%	30.82%	33.13%	34.67%	29.35%	29.37%	34.32%	39.97%	37.45%	30.48%
R&D to Revenue	14.02%	12.53%	13.62%	13.54%	15.36%	13.16%	13.48%	13.69%	16.05%	14.27%	14.33%
Operating Expenses to Revenue	43.95%	41.93%	44.44%	46.67%	50.03%	42.50%	42.85%	48.01%	56.02%	51.02%	45.05%
Earnings before Interest and Taxes (EBIT)	154	211	177	188	133	246	240	159	65	124	146
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	214	269	233	240	185	299	289	203	106	160	185
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	11.77	14.45	13.57	18.52	23.85	23.18	15.96	23.72	20.10	20.52	17.33
Price to Tangible Book Value (P/TBV)	12.42	15.37	14.53	19.63	25.52	25.12	17.25	25.94	21.97	22.63	17.81
Price to Revenue (P/Rev)	6.43	7.53	6.79	11.46	14.10	13.24	10.63	15.58	14.85	15.03	11.32
Price to Earnings (P/E)	49.86	52.72	39.46	67.61	83.83	88.54	95.99	139.34	153.48	128.19	129.53
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	2.01%	1.90%	2.53%	1.48%	1.19%	1.13%	1.04%	0.72%	0.65%	0.78%	0.77%
Enterprise Value to Invested Capital (EV/IC)	13.16	15.39	13.92	25.35	29.75	26.79	22.41	29.60	27.05	26.28	21.96
Enterprise Value to Revenue (EV/Rev)	6.37	7.50	6.78	11.29	13.97	13.16	10.43	15.44	14.66	14.86	11.18
Enterprise Value to EBITDA (EV/EBITDA)	27.64	32.63	28.04	43.87	54.47	53.16	46.83	75.41	76.97	79.12	76.01
Enterprise Value to EBIT (EV/EBIT)	36.16	42.65	36.04	55.03	68.25	67.08	60.35	99.95	106.79	110.68	120.52
Enterprise Value to NOPAT (EV/NOPAT)	57.04	62.01	46.65	78.84	99.28	104.60	111.14	155.09	159.88	126.64	126.73
Enterprise Value to Operating Cash Flow (EV/OCF)	27.41	30.56	32.63	49.82	66.22	63.67	47.50	64.02	58.76	64.61	48.56
Enterprise Value to Free Cash Flow (EV/FCFF)	109.85	100.22	115.26	92.43	137.26	147.63	226.66	417.71	416.42	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	1.08	1.16	1.23	1.00	1.08	1.18	1.13	1.53	0.88	0.92	1.08
Long-Term Debt to Equity	0.55	0.59	1.23	1.00	1.08	1.18	1.07	1.16	0.54	0.56	1.08
Financial Leverage	-0.16	-0.10	-0.17	-0.25	-0.24	-0.18	-0.27	-0.28	-0.30	-0.30	-0.35
Leverage Ratio	2.93	3.06	3.05	3.00	2.68	2.78	2.81	2.76	2.39	2.47	2.44
Compound Leverage Factor	2.93	3.06	3.05	3.00	2.68	2.78	2.81	2.76	2.39	2.66	2.44
Debt to Total Capital	51.88%	53.73%	55.21%	50.04%	52.02%	54.06%	52.99%	60.41%	46.89%	48.03%	51.90%
Short-Term Debt to Total Capital	25.59%	26.51%	0.00%	0.00%	0.00%	0.00%	2.57%	14.59%	18.39%	18.83%	0.00%
Long-Term Debt to Total Capital	26.29%	27.22%	55.21%	50.04%	52.02%	54.06%	50.42%	45.82%	28.50%	29.20%	51.90%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	48.12%	46.27%	44.79%	49.96%	47.98%	45.94%	47.01%	39.59%	53.11%	51.97%	48.10%
Debt to EBITDA	2.56	2.63	2.55	2.41	2.50	2.72	3.37	4.89	3.43	3.60	4.79
Net Debt to EBITDA	-0.27	-0.15	-0.06	-0.67	-0.47	-0.32	-0.90	-0.66	-1.03	-0.89	-0.98
Long-Term Debt to EBITDA	1.30	1.33	2.55	2.41	2.50	2.72	3.21	3.71	2.08	2.19	4.79
Debt to NOPAT	5.27	5.01	4.24	4.33	4.55	5.34	8.00	10.06	7.12	5.77	7.99
Net Debt to NOPAT	-0.56	-0.28	-0.09	-1.21	-0.86	-0.64	-2.14	-1.36	-2.15	-1.42	-1.64
Long-Term Debt to NOPAT	2.67	2.54	4.24	4.33	4.55	5.34	7.61	7.63	4.33	3.51	7.99
Altman Z-Score	4.88	5.49	5.20	7.69	9.06	8.34	6.36	7.53	9.34	9.20	7.56
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	1.50	1.47	2.46	2.82	2.90	2.84	2.80	2.42	2.02	1.99	3.77
Quick Ratio	1.27	1.22	2.01	2.36	2.43	2.38	2.40	2.12	1.72	1.72	3.26
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-131	-50	-227	38	-36	93	-60	-107	-135	-267	-178
Operating Cash Flow to CapEx	211.26%	241.89%	179.41%	422.69%	367.66%	254.48%	534.13%	322.54%	208.03%	208.66%	270.98%
Free Cash Flow to Firm to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Operating Cash Flow Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.63	0.63	0.61	0.58	0.63	0.62	0.59	0.53	0.57	0.56	0.58
Accounts Receivable Turnover	3.89	4.07	4.42	4.64	4.71	4.29	5.04	4.88	5.12	4.74	5.11
Inventory Turnover	2.99	2.89	2.79	2.96	2.96	3.08	3.04	3.03	3.04	3.09	2.95
Fixed Asset Turnover	3.35	3.29	3.30	3.48	3.48	3.34	3.27	3.17	3.13	3.13	3.20
Accounts Payable Turnover	1.07	1.09	1.02	1.08	1.17	1.19	1.15	1.25	1.37	1.39	1.44
Days Sales Outstanding (DSO)	93.88	89.58	82.51	78.65	77.55	85.01	72.39	74.85	71.33	76.99	71.44
Days Inventory Outstanding (DIO)	122.26	126.13	130.69	123.39	123.31	118.57	120.18	120.38	120.24	118.03	123.54
Days Payable Outstanding (DPO)	340.25	335.36	357.24	339.32	311.37	307.58	317.27	291.97	266.27	262.15	254.09
Cash Conversion Cycle (CCC)	-124.11	-119.65	-144.04	-137.28	-110.52	-104.01	-124.70	-96.75	-74.70	-67.13	-59.11
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	2,009	1,965	1,926	1,751	1,786	1,779	1,584	1,669	1,638	1,646	1,421
Invested Capital Turnover	2.19	2.15	2.25	2.30	2.22	2.12	2.26	2.04	1.95	1.98	2.18
Increase / (Decrease) in Invested Capital	223	186	342	83	148	133	163	200	171	353	280
Enterprise Value (EV)	26,428	30,239	26,812	44,406	53,129	47,655	35,505	49,383	44,298	43,254	31,215
Market Capitalization	26,686	30,377	26,865	45,089	53,590	47,945	36,188	49,815	44,894	43,740	31,619
Book Value per Share	$5.80	$5.38	$4.94	$6.12	$5.76	$5.35	$5.85	$5.42	$5.78	$5.52	$4.65
Tangible Book Value per Share	$5.50	$5.06	$4.61	$5.77	$5.38	$4.94	$5.41	$4.95	$5.29	$5.00	$4.52
Total Capital	4,710	4,544	4,419	4,872	4,683	4,503	4,825	5,305	4,205	4,102	3,793
Total Debt	2,443	2,441	2,440	2,438	2,436	2,434	2,557	3,204	1,972	1,970	1,969
Total Long-Term Debt	1,238	1,237	2,440	2,438	2,436	2,434	2,432	2,431	1,199	1,198	1,969
Net Debt	-258	-138	-53	-683	-461	-290	-684	-432	-595	-486	-403
Capital Expenditures (CapEx)	87	125	111	66	57	53	50	59	75	64	108
Debt-free, Cash-free Net Working Capital (DFCFNWC)	21	-5.60	36	5.50	130	146	-96	71	109	146	126
Debt-free Net Working Capital (DFNWC)	2,722	2,574	2,528	3,126	3,027	2,870	3,144	3,707	2,676	2,602	2,498
Net Working Capital (NWC)	1,517	1,369	2,528	3,126	3,027	2,870	3,020	2,933	1,902	1,830	2,498
Net Nonoperating Expense (NNE)	-14	-16	-19	-23	-35	-31	-18	-23	-13	-5.38	0.90
Net Nonoperating Obligations (NNO)	-258	-138	-53	-683	-461	-290	-684	-432	-595	-486	-403
Total Depreciation and Amortization (D&A)	60	58	55	52	53	53	48	44	42	36	39
Debt-free, Cash-free Net Working Capital to Revenue	0.50%	-0.14%	0.91%	0.14%	3.41%	4.03%	-2.83%	2.21%	3.59%	5.01%	4.52%
Debt-free Net Working Capital to Revenue	65.62%	63.82%	63.94%	79.45%	79.61%	79.23%	92.39%	115.93%	88.52%	89.43%	89.44%
Net Working Capital to Revenue	36.56%	33.95%	63.94%	79.45%	79.61%	79.23%	88.74%	91.73%	62.94%	62.87%	89.44%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$0.27	$0.38	$0.34	$0.36	$0.38	$0.66	$0.31	$0.30	$0.13	$0.24	$0.26
Adjusted Weighted Average Basic Shares Outstanding	391.10M	393.60M	394.20M	399.20M	390.20M	386M	386.60M	386.70M	386.70M	389.40M	389.80M
Adjusted Diluted Earnings per Share	$0.27	$0.37	$0.34	$0.35	$0.36	$0.66	$0.29	$0.28	$0.12	$0.24	$0.24
Adjusted Weighted Average Diluted Shares Outstanding	407.50M	412.70M	410.20M	416.80M	416.70M	425.50M	426.80M	431.50M	418.50M	427.50M	425.80M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.66	$0.00	$0.00	$0.00	$0.24	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	392.11M	390.77M	390.60M	400.73M	397.68M	385.52M	386.37M	387.87M	387.64M	386.41M	386.26M
Normalized Net Operating Profit after Tax (NOPAT)	91	136	115	121	71	152	103	93	36	86	102
Normalized NOPAT Margin	8.82%	12.18%	11.60%	12.02%	7.68%	14.68%	10.58%	10.70%	4.80%	10.60%	13.27%
Pre Tax Income Margin	14.89%	18.98%	17.84%	18.70%	14.39%	23.80%	24.66%	18.28%	8.70%	16.34%	19.00%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EBIT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
NOPAT Less CapEx to Interest Expense	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	0.00%	130.16%	183.61%	74.97%	0.00%	127.18%	50.05%	208.78%	0.00%	163.45%	228.47%

Frequently Asked Questions About DexCom's Financials

When does DexCom's fiscal year end?

According to the most recent income statement we have on file, DexCom's financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has DexCom's net income changed over the last 9 years?

DexCom's net income appears to be on an upward trend, with a most recent value of $576.20 million in 2024, falling from -$57.60 million in 2015. The previous period was $541.50 million in 2023. See DexCom's forecast for analyst expectations on what’s next for the company.

What is DexCom's operating income?

DexCom's total operating income in 2024 was $600 million, based on the following breakdown:

Total Gross Profit: $2.44 billion
Total Operating Expenses: $1.84 billion

How has DexCom revenue changed over the last 9 years?

Over the last 9 years, DexCom's total revenue changed from $402 million in 2015 to $4.03 billion in 2024, a change of 903.2%.

How much debt does DexCom have?

DexCom's total liabilities were at $4.38 billion at the end of 2024, a 4.4% increase from 2023, and a 6,089.1% increase since 2015.

How much cash does DexCom have?

In the past 9 years, DexCom's cash and equivalents has ranged from $86.10 million in 2015 to $1.14 billion in 2018, and is currently $606.10 million as of their latest financial filing in 2024.

How has DexCom's book value per share changed over the last 9 years?

Over the last 9 years, DexCom's book value per share changed from 2.72 in 2015 to 5.38 in 2024, a change of 97.8%.

Related Companies

This page (NASDAQ:DXCM) was last updated on 5/29/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

DexCom (DXCM) Financials

Frequently Asked Questions About DexCom's Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

DexCom (DXCM) Financials

Annual Income Statements for DexCom

Quarterly Income Statements for DexCom

Annual Cash Flow Statements for DexCom

Quarterly Cash Flow Statements for DexCom

Annual Balance Sheets for DexCom

Quarterly Balance Sheets for DexCom

Annual Metrics And Ratios for DexCom

Quarterly Metrics And Ratios for DexCom

Frequently Asked Questions About DexCom's Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools